Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest German inventions Stories

2012-06-14 06:24:41

CHADDS FORD, Pa., June 14, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP), today announced the completion of the company's transition of its OPANA ER franchise to the new formulation designed to be crush resistant. In connection with the completion of this transition, the U.S. Food and Drug Administration (FDA) has moved the old formulation of OPANA ER to the Orange Book Discontinued List. "While the original formulation of OPANA ER was deemed by FDA to be safe and effective when...

2012-06-07 02:28:09

SAN FRANCISCO, June 7, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that the U.S. Food and Drug Administration (FDA) has designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain. NKTR-181 is a novel mu-opioid agonist molecule, which is designed to have a slow rate of entry into the brain to reduce the attractiveness of the molecule as a target of abuse and to reduce its CNS-mediated side effects. NKTR-181 was...

2012-06-04 06:26:54

STAMFORD, Conn., June 4, 2012 /PRNewswire/ -- Purdue Pharma L.P. will present data evaluating physician understanding of the Risk Evaluation and Mitigation Strategy (or REMS) for Butrans® (buprenorphine) Transdermal System CIII at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting. The data includes results from a post-test evaluation of prescribers who completed Butrans REMS training between December 2010 and February 2011....

2012-05-31 02:25:53

PISGAH FOREST, N.C., May 31, 2012 /PRNewswire/ -- Pisgah Laboratories, Inc. (www.pisgahlabs.com) received Notice of Allowance from the United States Patent and Trademark Office (www.uspto.gov) for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties." Pisgah began pursuing a technology platform in 2006 that addresses the nation's drug abuse epidemic and this patent is the first in what is expected to be a large estate of allowed...

2012-05-23 02:26:47

SYDNEY and BEDMINSTER, N.J., May 23, 2012 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 8,182,837, which does not expire until 2023. This patent covers a method of treatment of pain comprising the administration of the oral Dual Opioid®( )compositions of MoxDuo IR (Immediate Release) for the treatment of acute pain as well as MoxDuo CR (Controlled Release) for the...

2012-05-18 06:24:58

STAMFORD, Conn., May 18, 2012 /PRNewswire/ -- Purdue Pharma L.P. will present an analysis of data from completed clinical trials for Butrans®( )(buprenorphine) Transdermal System CIII at the American Pain Society's (APS) 31st Annual Scientific Meeting. The analysis includes an evaluation of supplemental analgesic use and pain scores across the 7-day dosing interval. (Logo: http://photos.prnewswire.com/prnh/20100921/NY67262 ) The poster will be presented at the APS meeting in...

2012-05-17 10:25:19

RARITAN, N.J., May 17, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA® ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy (DPN). Results of the study were presented at the 31st Annual Scientific Meeting of the American Pain Society being held May 16-19 in...

2012-05-17 12:28:11

Regular exercise may help, according to new study in Pain Stories of athletes bravely "playing through the pain" are relatively common and support the widespread belief that they experience pain differently than non-athletes. Yet, the scientific data on pain perception in athletes has been inconsistent, and sometimes contradictory. Investigators from the University of Heidelberg have conducted a meta-analysis of available research and find that in fact, athletes can indeed tolerate a...

2012-05-17 06:25:33

BALTIMORE, May 17, 2012 /PRNewswire/ -- Ameritox (SM), the nation's leader in pain medication monitoring, announced today the presentation of a peer-reviewed scientific poster titled "Patterns of Drug Use in the Older Chronic Pain Population" at the American Pain Society Annual Meeting. Ameritox researchers will share analysis from 725,679 urine drug monitoring samples from chronic pain patients aged 50 and older. Data show almost one-third (31.8 percent) lacked the...

2012-05-17 06:23:39

SAN DIEGO, May 17, 2012 /PRNewswire/ -- The Millennium Research Institute (MRI), a nonprofit national research center formed in 2010, and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego (UCSD) announced today five scientific articles co-authored by UCSD doctoral pharmacy students have been accepted by the Journal of Analytical Toxicology (JAT). The articles, which address metabolism of medications including hydrocodone, hydromorphone,...